Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVICTI versus sodium phenylbutyrate in phenylbutyrate-naive patients with urea cycle disorders
2015-000075-27Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium phenylbutyrate in urea cycle disorder (UCD) (2 arms), sponsored by Horizon Therapeutics. Primary endpoint: Rate of Treatment Success. Started Nov 2015; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on 2015-000075-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000075-27.